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Objectives: This study evaluated the analytical characteristics of the LiaisonR immunoassay for cardiac troponin I (cTnI).
Design and methods: The protocol consisted of eight sections: evaluation of antibody specificity, linearity, detection limit and
imprecision, method comparison, evaluation of endogenous interferents, anticoagulant interference, sample stability, and reference values.
Results: The assay equally measured free and complexed cTnI. The minimum detectable cTnI concentration was 0.021 Ag/l. The cTnI
concentration corresponding to a total CVof 10% was 0.056 Ag/l. Linearity of response was demonstrated along the entire dynamic range of
the assay. Assay interferences were minimal. cTnI concentrations in serum and heparinized plasma were significantly different. Values in
EDTA plasma were on average approximately 5% higher than in matched serum, but this difference was not significant. The 99th percentile
cTnI value in healthy subjects was 0.036 Ag/l.
Conclusions: Being sensitive, specific, and precise, the LiaisonR cTnI assay meets current requirements to aid in the diagnosis of
myocardial necrosis.
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Introduction The redefined biochemical criterion proposed to classifyCardiac troponins are presently regarded as the most
cardiac-specific of currently available biochemical markers
for the diagnosis of myocardial injury [1]. In particular,
cardiac troponin I (cTnI) and cardiac troponin T (cTnT)
have been identified. These proteins are associated with
specific amino acid sequences encoded by genes different
from those encoding skeletal muscle isoforms. While cTnI
has been shown to have complete specificity for cardiac
muscle, cTnT is present in small amounts in skeletal
muscle during human fetal development and is reex-
pressed during diseases that involve skeletal muscle regen-
eration [2].0009-9120/$ - see front matter D 2004 The Canadian Society of Clinical Chemis
doi:10.1016/j.clinbiochem.2004.04.003
$ Presented in part at the 54th AACC National Meeting, July 28–
August 1, 2002, Orlando, FL (Clin. Chem. 2002;48:A85).
* Corresponding author. Fax: +39-030-3995369.
E-mail address: panteghi@bshosp.osp.unibs.it (M. Panteghini).acute coronary syndrome patients presenting with ischemic
symptoms as patients with acute myocardial infarction
(AMI) is heavily predicated on an increased cardiac tropo-
nin concentration in blood [3]. This necessitates the avail-
ability of highly specific, sensitive, and precise troponin
assays [4]. Some assays, however, are inadequately ap-
praised before their implementation in the laboratories [5].
More peer-reviewed studies are needed, and only well-
documented assays should be considered for clinical use.
The design control loop is indeed not closed until the
finished in vitro diagnostic system is adequately validated
to meet the customer needs, including the laboratory’s
analytical quality specifications [6].
The Committee on Standardization of Markers of Cardi-
ac Damage (C-SMCD) of the IFCC recently proposed
detailed quality specifications for cardiac troponin assays
with the objective to urge the scientific community to select
and design research projects on the major issues in troponints. All rights reserved.
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checked the conformity of the characteristics of a new
automated immunoassay for the determination of cTnI
(Liaison cTnI assay, DiaSorin—formerly Byk-Sangtec
Diagnostica-Saluggia VC, Italy) to quality issues addressed
in the above mentioned document.Materials and methods
The evaluation study was carried out at four European
centers located in Belgium (BE), France (FR), Germany
(GE), and Italy (IT). The Liaison analyzers and all other
materials used within the study were strictly handled
according to the manufacturer’s instructions. Unless other-
wise stated, fresh serum was used as sample. Human
(leftover) samples needed for different parts of the study
were provided by each participating center. If not otherwise
stated, all measurements were done in singlicate.
Assay method
The Liaison cTnI assay is a two-site immunoluminomet-
ric assay that uses a combination of a murine monoclonal
antibody (directed to amino acids 80–110 of cTnI molecule)
coated on paramagnetic particles (DynabeadsR, Dynal Bio-
tech, Oslo, Norway) and an affinity-purified polyclonal goat
antibody (directed to amino acids 27–39) labeled with
isoluminol, used for the tracer. One hundred-microliter
sample is added to 200-Al tracer and 20-Al antibody-coated
magnetic particles. After 10-min incubation, the particles are
separated and washed, and the chemiluminescent signal is
generated by injection of ready-to-use trigger solutions.
Time to the first result is approximately 15 min. The assay
calibration is performed by a two-point recalibration using a
stored master curve. The master curve covers the range from
0 to 100 Ag/l. A recombinant cTnI-troponin C binary
complex (cTnI stable fragment 28–110 linked to the full-
length troponin C) is used as calibration antigen [8].
Detection limit
The minimum detectable cTnI concentration was
assessed by 20 replicate measurements of the zero calibrator
in a single run and defined as the cTnI value corresponding
to a signal 3 SD greater than the mean found for this
sample. The experiment was performed at each of the four
institutions.
Antibody specificity
Reactivity against different forms of cTnI
Buffered stock solutions of both free cTnI and troponin
IC complex (IC), as obtained from Scripps Laboratories
(San Diego, CA), were serially diluted in appropriate
buffers to produce 5, 10, 20, and 100 Ag/l solutions ofcTnI and tested in duplicate. The ratio IC/I was calculated,
and the degree of equimolarity was estimated. Buffered
stock solutions of both phosphorylated (ph) and dephos-
phorylated (dp) cTnI, as obtained from HyTest Ltd. (Turku,
Finland), were serially diluted in appropriate buffer to
produce 1.5 and 3.0 Ag/l solutions of cTnI and analyzed
in duplicate. The ratio ph/dp was calculated, and the degree
of equimolarity was estimated. These experiments were
performed in IT.
Cross-reaction with skeletal muscle troponin I
Three serum samples from patients with acute rabdo-
myolysis [with total creatine kinase activity (measured at
37jC according to the IFCC-recommended method) of
42,900 U/l; 70,230 U/l; and 289,260 U/l, respectively] and
no overt cardiac involvement were determined in duplicate
in IT.
Linearity on dilution
Nine cTnI-rich serum samples (native concentrations,
from approximately 5 Ag/l to 80 Ag/l) were serially diluted
with serum pools having undetectable cTnI concentrations,
that is, lower than the detection limit of the Liaison assay.
The undiluted sample and three separate dilutions (3:4,
1:2, 1:4) were assayed in duplicate in the same analytical
run. The curve obtained was tested for linearity as sug-
gested by Burnett [9]. Linear regression analysis of the
data was also calculated. The experiments were carried out
in BE, FR, and IT.
Imprecision and calculation of 10% CV concentration
On the basis of NCCLS guideline EP5-A [10], each of
the four institutions tested the two Liaison control sera (low
and high, cat. no. 319119) in duplicate in 1 run/day for 20
days, using two lots of reagents and at least four calibrations
during the experiment. Within-run and total imprecision
were calculated for each control at each site. In a second
experiment (performed at IT), seven human serum pools
were prepared and stored at 80jC until used. The
corresponding cTnI concentrations were approximately
0.030, 0.050, 0.10, 0.40, 1.0, 5.0, and 10.0 Ag/l. Two
replicates per specimen per run and 1 run/day for 20
working days, by including two reagent lots (10 working
days  lot) and nine calibrations, were performed. Pools
were randomly analyzed to reflect any carryover effect. The
total CV at different concentrations was calculated, and the
CV values reported for the seven pools were used to
construct the imprecision profile for the method [7]. The
cTnI concentration corresponding to a total CV of 10% was
calculated by interpolating the obtained imprecision profile.
The same type of protocol (using only four human serum
pools with cTnI concentrations between 0.025 and 0.070
Ag/l) was repeated in BE to confirm the 10% CV cTnI
concentration obtained in the previous experiment.
iocheMethod comparison
The Liaison cTnI was compared with the Access
AccuTnIk (Beckman Coulter, Brea, CA) [11] using 134
serum samples randomly selected to represent the range of
cTnI values likely to be encountered in clinical practice. The
comparison data were analyzed by Deming regression and
bias plot.
Interference studies
All participating centers contributed to this part.
Endogenous interferents
Sera containing high concentrations of potentially inter-
fering substances, that is, hemoglobin, bilirubin, and trigly-
cerides, were diluted with cTnI-rich sera, and the recovery
of cTnI was calculated. To test possible interference by
paraproteins, three serum samples from patients with mul-
tiple myeloma, total protein concentrations in serum from
98 to 128 g/l (monoclonal protein concentrations in g-region
at electrophoresis from 45.4 to 87.8 g/l), and no overt
cardiac involvement were determined in duplicate. To test
interferences by rheumatoid factor (RF) and human anti-
mouse antibodies (HAMA), 10 samples with high RF
concentrations [634–2480 kU/l, when determined with a
rate-nephelometric latex method—previously established
upper reference limit (URL), 20 kU/l] and 19 samples
containing HAMA (obtained by Scantibodies Laboratory,
Inc., Santee, CA) were analyzed in duplicate before and
after the treatment with heterophilic blocking tubes (HBT)
(Scantibodies Laboratory). Treatment of samples with HBT
was performed according to the manufacturer’s instructions.
Briefly, 500-Al sample was added to HBT and mixed with
the blocking reagent present in the form of a lyophilized
pellet at the bottom of the tube. cTnI measurement was
performed after 1-h incubation at room temperature (RT). A
high cTnI sample from a patient with AMI was also used by
each participating center as a negative control of the HBT
treatment, by measuring it before and after the treatment. All
the measurements related to the same sample (before and
after the treatment) were carried out in the same run.
Sample type
A total of 124 paired samples, obtained from AMI
patients in both early, that is, <12 h, and late phases after
symptom onset, were studied. After informed consent, three
separate tubes were collected for each patient in random
order during the same phlebotomy to prepare serum, heparin
(lithium) plasma, and EDTA plasma specimens. cTnI assay
was performed in duplicate on each of the three different
specimens in the same analytical run. The mean results on
plasma samples were compared with the paired serum
values, and the significance of the differences was evaluated
(Wilcoxon rank sum test). Linear regression analyses and
bias plots were also performed.
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Two pooled cTnI-rich serum specimens were analyzed
within 2 h of collection (T0). The samples were then divided
into four aliquots. Aliquot A was kept at RT, and small
aliquots from this sample A were analyzed after 8, 24, 48,
and 72 h. Another aliquot (B) was placed in a refrigerator
(+4jC) and analyzed after 24, 48, 96, and 168 h. The third
aliquot (C) was maintained at 20jC and analyzed after 2,
7, 14, 21 days and 1, 3, and 6 months. The fourth aliquot
(D) was kept at 80jC and analyzed after 3 and 6 months.
Before analysis, the frozen samples were thawed at RT,
mixed, and centrifuged to remove any particulate material.
All measurements were done in duplicate in IT. Recovery of
cTnI was calculated as percentage of the initial value
obtained on fresh samples by dividing the concentrations
at any storage time (Th) by the concentration at T0. The
statistical analysis of trend was also done. Recoveries for
fresh serum samples (n = 4) and samples frozen for 1, 3, and
6 months at 20jC were also performed in GE and IT.
Reference values
Serum specimens from 128 apparently healthy individu-
als (53 women and 75 men; age range, 40–80 years) were
analyzed. The subjects were drawn from a population of
Caucasian blood donors and a priori selected using the IFCC
recommendations for the production of reference values
[12]. cTnI was measured, and the 99th percentile of the
value distribution was calculated using nonparametric deter-
mination of percentiles. This study was performed in IT.
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Detection limit
The detection limit ranged from 0.019 to 0.023 Ag/l (no.
of experiments, 7) with a median of 0.021 Ag/l.
Antibody specificity
The assay equally measured free cTnI and cTnI com-
plexed with troponin C (mean IC/I ratio F SE, 1.01 F 0.05;
P = 0.87; n = 4). No difference in the reactivity of the
antibodies used in the kit against ph and dp cTnI was also
demonstrated (mean ph/dp ratio F SE, 1.06 F 0.05; P =
0.46; n = 2). In all three samples from patients with
rabdomyolysis, cTnI by Liaison was undetectable, that is,
<0.02 Ag/l.
Linearity on dilution
The results of linearity studies are shown in Table 1. As
can be seen, the hypothesis of a linear fit was accepted for
all the samples tested.
Fig. 1. Imprecision results for human serum pools measured with Liaison
cardiac troponin I (cTnI) assay. The cTnI concentration corresponding to
the 10% total CV is shown by the arrow.
Table 1
Results of linearity studies
Sample ID cTnI native
concentration,
Ag/l
F test Pa r
1 BE 83.1 80.0 0.11 0.9997
3 IT 79.6 78.6 0.11 0.9977
2 FR 52.3 0.06 0.82 0.9999
2 IT 41.9 0.61 0.57 0.9995
1 FR 38.3 1268 0.07 0.9990
4 FR 20.1 12.3 0.20 0.9973
3 FR 14.5 0.15 0.75 0.9986
1 IT 9.0 33.2 0.14 0.9951
2 BE 4.5 5.14 0.27 0.9916
a The hypothesis of a linear fit is rejected with P < 0.05.
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The within-run and total imprecision (CV) of the two
controls (company’s established ranges, 0.035–0.051 and
0.87–1.07) were 1.3–11.1% and 2.8–11.6%, respective-
ly, across two lots of reagents and four institutions
(Table 2).
Fig. 1 displays the imprecision profile (total % CV vs.
pools having increasing cTnI concentrations) obtained for
Lia ison cTnI method. The cTnI concentrat ion
corresponding to a total CV of 10%, calculated by inter-
polating the obtained imprecision profile, was 0.054 Ag/l.
From the data of a second similar experiment, we also
calculated the cTnI concentration at 10% CV which was
found to be 0.057 Ag/l.
Method comparison
Method comparison produced evidence of proportional
(slope, 0.38 F 0.03) and constant bias (intercept, 0.24 F
0.13 Ag/l), underscoring the need of cTnI standardization
(Fig. 2). Although the compared methods showed a signif-
icant systematic bias, there was good correlation when
assays were compared (r = 0.978).Table 2
Imprecision data from four institutions with two lots of reagents over 20
analytical runs
Site
BEa FRb GEc ITa
Control 1 (lot 7201), Ag/l 0.045 0.039 0.044 0.043
Within-run CV, % 7.7 11.1 7.6 7.9
Total CV, % 8.6 11.6 8.3 9.2
Control 2 (lot 7201), Ag/l 0.95 0.99 0.95 0.96
Within-run CV, % 2.1 1.3 2.9 1.6
Total CV, % 2.8 4.0 3.6 3.4
a Nine calibrations performed.
b Four calibrations performed.
c Eight calibrations performed.Interfering substances
No interferences with test results were seen by concen-
trations of bilirubin <12.5 mg/dL, hemoglobin <5 g/l, and
triglycerides <1200 mg/dL. cTnI recoveries were within
95–105%. In samples from patients with myeloma, cTnI
by Liaison was always undetectable, that is, <0.02 Ag/l.
None of 10 RF samples tested above 0.02 Ag/l. Only one
HAMA sample (0.08 Ag/l) tested above the detection limit
of the assay. However, incubation of this sample in HBT did
not cause a decrease of the cTnI value. As in a recent study,
in 21% of cases, the interference by heterophilic antibodies
was demonstrated only by showing nonlinearity in dilution
studies and not by blocking studies [13], the sample was
diluted with a negative (undetectable) cTnI serum pool to
give separate 3:4 and 1:2 serial dilutions. The undiluted and
diluted samples were then reanalyzed in the same run. Good
linearity on dilution was, however, demonstrated (r =
0.989). Thus, it does not appear that this case of nonnegative
cTnI was the result of the presence of an interfering
antibody, but it was likely enough that this sample contained
true cTnI.
Sample type
Table 3 shows the results of the comparison studies
performed on anticoagulant samples in each institution.
Since different types of sampling tubes and different times
of blood collection after AMI (data not shown) did not
influence the obtained results, the data were evaluated all
together (Fig. 3). On average, the difference (95% confi-
dence interval) for heparin samples was 26.7% (29.0%
to 24.4%; P < 0.0001), and the difference for EDTA was
4.7% (1.7% to 7.6%; P = 0.63).
Sample stability
Serum samples (pooled) were stable for at least 72 h at
RT (mean cTnI recovery F SE, 106.0% F 9.7%, P z
0.06), 7 days at 4jC (mean cTnI recovery F SE, 98.5% F
Fig. 2. Method comparison and plot of the differences (in percentage) between Liaison and Access cardiac troponin I (cTnI) assays (n = 134). CI, confidence
interval.
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SE, 104.5% F 4.9%, P z 0.14), and 6 months at 80jC
(mean cTnI recovery F SE, 102.7% F 0.8%, P z 0.83).
For one sample (cTnI concentration at T0, 6.63 Ag/l), a
significant positive trend (P = 0.0004) was observed when
stored for more than 1 month at 20jC. To further evaluate
stability at 20jC, four additional samples from individual
patients were studied. Again, all samples were stable for 1
month (mean cTnI recovery F SE, 105.2% F 2.6%);
however, two samples from two different centers (cTnI
concentrations at T0, 12.9 and 23.3 Ag/l, respectively)
showed a significant cTnI increase (P = 0.00004 and P =
0.021, respectively) during prolonged storage.
Reference values
Ninety-three percent of cTnI values from the selected
subjects were undetectable, that is, <0.02 Ag/l, and only
nine subjects (four males and five females) showed a
measurable cTnI concentration. The calculated 99th percen-Table 3













0.073–92.7 Heparin vs. serum:
y = 0.82  0.52
EDTA vs. serum:







0.028–49.7 Heparin vs. serum:
y = 0.75  0.01
0.9705 <0.001
EDTA vs. serum:
y = 0.91  +0.10
0.9973 0.08
GE 30 Sarstedt 0.022–21.4 Heparin vs. serum:
y = 0.68  +0.12
0.9970 <0.001
EDTA vs. serum:
y = 0.93  +0.13
0.9949 0.13
IT 13 Sarstedt 0.052–48.8 Heparin vs. serum:
y = 0.40  +0.44
0.9918 <0.001
EDTA vs. serum:
y = 0.85  +0.57
0.9980 0.02
a Serum in x-axis.
b Wilcoxon rank sum test for paired samples.tile of the cTnI value distribution was 0.036 Ag/l, with no
sex- or age-related differences. From data of imprecision
studies, the total CV corresponding to this concentration
was 13.5%.Discussion
Despite the overt clinical advantages, important analyti-
cal and preanalytical obstacles to cardiac troponin analysis
and interpretation remain, such as assay standardization,
antibody specificity, interferences, preanalytical factors, and
assay imprecision [4,5]. Some commercial assays are re-
leased without collecting and publishing thorough informa-
tion related to these sources of variability. The quality of a
method and its analytical performance characteristics should
be judged against objective quality specifications, for ex-
ample, published state-of-the-art data or recommendations
documented by expert professional groups. On this partic-
ular topic, a document on quality specifications for cardiac
troponin assays has been prepared by C-SMCD of the IFCC
[7]. The goals of this document were that (a) manufacturers
address the enclosed recommendations; (b) package inserts
include adequate information on method design, as well as
on preanalytical and analytical performance characteristics;
and (c) the scientific community selects research projects
that are primarily concerned with the addressed issues. The
present study, evaluating the analytical performance of the
new Liaison cTnI assay, has been designed and performed
to fulfill these recommendations.
The assay calibration strictly followed the IFCC specifi-
cations, which recommend the use of a material representing
the natural and major form of cTnI in blood after tissue
release, that is, the complexed form [7]. A recombinant
single-chain cTnI-troponin C polypeptide, previously very
well characterized [8], was selected by the manufacturer and
employed as calibration material to obtain the 10-point
calibration curve.
The specificity of the antibody pairs used in the assay
was examined with respect to the major circulating forms of
cTnI, that is, the free protein, its binary IC complex, and the
ph and dp forms, demonstrating that the assay has an
Fig. 3. Correlation studies and difference plots (in percentage) of serum and plasma samples (n = 124) measured by Liaison cardiac troponin I (cTnI) assay. CI,
confidence interval.
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Liaison antibodies, associated with their ability to recognize
epitopes located in the stable part of cTnI, warrants optimal
assay performance with regard to the antibody specificity.
We did not test the effect of oxidation, because the oxidized
cTnI form is not commercially available for experiments.
However, the stability data at RT reported in our study
imply that this should not be a significant source of assay
variation.
Linearity of response was demonstrated with no signif-
icant deviations along the entire dynamic range of the assay.
Cross-reactivity and assay interference were minimal. In
particular, since the lack of in vitro cross-reaction with other
troponin molecules, that is, skeletal muscle troponin I, cTnT,
and troponin C, had already been demonstrated by the
manufacturer [14], we focused on possible in vivo interfer-
ences. The absence of measurable cTnI in sera from patients
with severe rabdomyolysis and no cardiac involvement
demonstrates no cross-reaction with noncardiac troponins,
such as skeletal muscle troponins, and other potentially
interfering muscular proteins.
The LiaisonR assay provided reproducible results within
the run and from run to run, lot to lot, and site to site. The
imprecision was evaluated in two ways. One using com-
mercial controls showed good imprecision even for the low
control, which was close to the 99th percentile URL. The
other approach was to define the imprecision profile using
the protocol recommended by IFCC to obtain a realistic
indication of the variation of cTnI measurements especially
at low-range concentrations [7,15]. For this latter study,
pools of human sera were used. Since the C-SMCD recom-mends a total imprecision (CV) of V10% at the AMI
decision limit, the lowest concentration with this impreci-
sion was derived, that is, 0.056 Ag/l (mean of two indepen-
dent experiments). This value exceeds the 99th percentile
URL (0.036 Ag/l), the theoretically defined AMI cut-off in
the Joint European Society of Cardiology/American College
of Cardiology document [3]. As recently shown in a
comprehensive study [15], there are currently no commer-
cial assays that can achieve the 10% CV recommendation at
99th percentile URL, so that, in the context of clinical
practice, the use of a predetermined cTnI concentration that
meets the 10% imprecision goal as an AMI cut-off has been
suggested [16,17]. The use of the actual 10% CV concen-
tration instead of 99th percentile URL as a decision cut-off
could slightly decrease the clinical sensitivity of the bio-
chemical criterion used for the AMI diagnosis but should
permit the physician to avoid the occasional increase in
serum cTnI in the absence of myocardial damage [18]. The
LiaisonR cTnI assay revealed excellent performance if
compared with data published for other commercial systems
[15] and was quite close to meet the 10% CV at URL,
demonstrating a 10%/99th ratio of 1.6. Our results corrob-
orate those from a recent collaborative study in which the
imprecision experiments directly performed by the assay
manufacturer gave a 10% CV value of 0.065 Ag/l and a ratio
of 2.2 [15]. Conversely, our findings from the imprecision
studies are different from those published in a study show-
ing a 10% CV at 0.027 Ag/l [19]. However, these authors
calculated the imprecision profile from duplicates, thus
considering only within-run variation. Although higher
precision at lower cTnI concentrations does not automati-
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that the use of a high sensitivity cTnI assay would identify a
substantial and additional proportion of patients with AMI
compared with a less sensitive cTnI assay [20].
In the current study, the LiaisonR assay detected cTnI in
7% of healthy people, whereas in a separate clinical study,
the same assay was able to detect cTnI in 37% of the healthy
individuals [19]. Aspects such as criteria for individual
selection, sample size, or statistical data analysis should
be considered to explain this difference. However, two
additional analytical aspects should also be noted in the
mentioned study: the use of EDTA samples, potentially
giving higher cTnI results in the low-range concentrations
(see Fig. 3), and the acritical acceptance of the manufactur-
er-declared detection limit (0.005 Ag/l), possibly too low if
compared with the data experimentally obtained in this
multicenter evaluation (0.021 Ag/l).
The in vitro stability of cTnI appears to be method-
dependent, creating a need for data for each commercially
available new assay [7]. We appropriately studied the
effect of storage on apparent cTnI concentrations, giving
information on stability at different storage temperatures.
In particular, we confirmed and extended previous prelim-
inary data evaluating stability only at RT and in the
refrigerator [21].
The use of plasma instead of serum samples for cTnI
determination can be very useful because it eliminates the
extra time needed for clotting, thereby reducing the overall
preanalytical time [22]. However, there can be significant
differences between serum and plasma concentrations of
cTnI, so that the use of anticoagulants should be studied and
validated thoroughly before it can be recommended for
practical use [7]. According to previous preliminary results
[23], the use of heparinized plasma samples in the LiaisonR
assay led to significantly lower recoveries for cTnI. It is well
known that binding of heparin to cardiac troponins may
reduce their immunoreactivity to various degrees, depend-
ing on the assay epitopes and conformational changes in the
molecule, and that these losses of troponin immunoreactiv-
ity can be dependent upon time elapsed from onset of
myocardial necrosis to sample collection [24]. However,
the epitope recognition of the LiaisonR antibodies, which is
not affected by heparin, and the lack of the time dependence
of heparin interference on this assay seem to indicate that
the effect of this negatively charged glycosaminoglycan is
primarily indirect, possibly induced by changes within the
sample matrix itself [25]. We also showed that values in
EDTA plasma were on average approximately 5% higher
than in matched serum samples. The mechanism for this
slight (not significant) bias is not completely understood,
even if the classic effect of EDTA as calcium chelator,
splitting the calcium-dependent troponin complexes, was
excluded on the basis of our data showing assay equimo-
larity. The significant scattering of the data points at low
cTnI concentrations could partly explain this result. For
practical use, EDTA plasma samples are acceptable forLiaisonR cTnI, but different decision limits may be required
for this sample type.
In conclusion, the LiaisonR cTnI assay system provides
sensitive, specific, and precise determination of cTnI, meet-
ing current requirements to aid in the AMI diagnosis. As
already shown [19], the robustness of this assay at low-
range concentrations can also permit its profitable utilization
in the prognostic assessment of patients with unstable
coronary disease.Acknowledgments
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